Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease

Seminars in Dialysis

Volumn 23, Issue 4, 2010, Pages 378-382

  Siew, Edward D ^a   Ikizler, Talat Alp ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MUSCLE PROTEIN;

ARTICLE; CALORIC INTAKE; CHRONIC KIDNEY FAILURE; ENERGY METABOLISM; HOSPITALIZATION; HUMAN; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

ENERGY INTAKE; ENERGY METABOLISM; HUMANS; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MUSCLE PROTEINS; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 77955249418     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00763.x     Document Type: Article

References (40)

1. Excerpts from the USRDS 2001 Annual Data Report. Am J Kidney Dis 2001, 38:S1-S248.
2. Zubrod CG, Eversole SL, Dana GW. Amelioration of diabetes and striking rarity of acidosis in patients with Kimmelstiel-Wilson lesions. N Engl J Med 1951, 245:518-528.
3. Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med 1970, 282:182-187.
4. DeFronzo RA, Smith D, Alvestrand A. Insulin action in uremia. Kidney Int Suppl 1983, 16:S102-S114.
5. Price SR, Du JD, Bailey JL, Mitch WE. Molecular mechanisms regulating protein turnover in muscle. Am J Kidney Dis 2001, 37:S112-S114.
6. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004, 15:1537-1545.
7. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004, 140:167-174.
8. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005, 16:2134-2140.
9. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002, 19:527-534.
10. Shoji T, Emoto M, Nishizawa Y. HOMA index to assess insulin resistance in renal failure patients. Nephron 2001, 89:348-349.
11. Inoue M, Maehata E, Yano M, Taniyama M, Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism 2005, 54:281-286.
12. Kiec-Klimczak M, Malczewska-Malec M, Huszno B. Leptin to adiponectin ratio, as an index of insulin resistance and atherosclerosis development. Przegl Lek 2008, 65:844-849.
13. Kotani K, Sakane N, Saiga K, Kurozawa Y. Leptin: adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness. Diabetologia 2005, 48:2684-2686.
14. Kumagai S, Kishimoto H, Suwa M, Zou B, Sasaki H. The leptin to adiponectin ratio is a good biomarker for the prevalence of metabolic syndrome, dependent on visceral fat accumulation and endurance fitness in obese patients with diabetes mellitus. Metab Syndr Relat Disord 2005, 3:85-94.
15. Oda N, Imamura S, Fujita T. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism 2008, 57:268-273.
16. Zaletel J, Barlovic DP, Prezelj J. Adiponectin-leptin ratio: a useful estimate of insulin resistance in patients with type 2 diabetes. J Endocrinol Invest 2010, [Epub ahead of print]
17. Matsuhisa M, Yamasaki Y, Emoto M. A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects. Diabetes Res Clin Pract 2007, 77:151-154.
18. Finucane FM, Luan J, Wareham NJ. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 2009, 52:2345-2349.
19. Inoue M, Yano M, Yamakado M, Maehata E, Suzuki S. Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metabolism 2006, 55:1248-1254.
20. Zeman M, Jirak R, Jachymova M, Vecka M, Tvrzicka E, Zak A. Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. Neuro Endocrinol Lett 2009, 30:387-395.
21. Zhuo Q, Wang Z, Fu P. Comparison of adiponectin, leptin and leptin to adiponectin ratio as diagnostic marker for metabolic syndrome in older adults of Chinese major cities. Diabetes Res Clin Pract 2009, 84:27-33.
22. Teta D, Maillard M, Halabi G, Burnier M. The leptin/adiponectin ratio: potential implications for peritoneal dialysis. Kidney Int Suppl 2008, 73(108):S112-S118.
23. Ikizler TA. Nutrition, inflammation and chronic kidney disease. Curr Opin Nephrol Hypertens 2008, 17:162-167.
24. Bergstrom J, Lindholm B, Lacson E. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 2000, 13:163-175.
25. Du J, Wang X, Miereles C. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004, 113:115-123.
26. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005, 54:2939-2945.
27. Larsen CM, Faulenbach M, Vaag A. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356:1517-1526.
28. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998, 53:1353-1357.
29. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986, 119:84-90.
30. Trirogoff ML, Shintani A, Himmelfarb J, Ikizler TA. Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3-4 chronic kidney disease patients. Am J Clin Nutr 2007, 86:1642-1648.
31. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007, 71:146-152.
32. Hung AM, Sundell M, Ellis C, Sha F, Ikizler TA. HOMA-adiponectin index of insulin sensitivity is the best correlate of euglycemic-hyperinsulinemic clamp (HEGC) in CHD patients. J Am Soc Nephrol 2009, 20:239. Abstract
33. Flakoll PJ, Carlson M, Cherrington AC. Physiological action of insulin. Diabetes Mellitus: A fundamental and Clinical Text 2000, 148-161. Leroith DTS, Olefsky J, In, eds, 2nd edn, Philadelpia, PA, Williams & Wilkins
34. Siew ED, Ikizler TA. Determinants of insulin resistance and its effects on protein metabolism in patients with advanced chronic kidney disease. Contrib Nephrol 2008, 161:138-144.
35. Biolo G, Inchiostro S, Tiengo A, Tessari P. Regulation of postprandial whole-body proteolysis in insulin-deprived IDDM. Diabetes 1995, 44:203-209.
36. Bohe J, Rennie MJ. Muscle protein metabolism during hemodialysis. J Ren Nutr 2006, 16:3-16.
37. Lim VS, Yarasheski KE, Crowley JR, Fangman J, Flanigan M. Insulin is protein-anabolic in chronic renal failure patients. J Am Soc Nephrol 2003, 14:2297-2304.
38. Pupim LB, Flakoll PJ, Majchrzak KM, Aftab Guy DL, Stenvinkel P, Ikizler TA. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int 2005, 68:1857-1865.
39. Pupim LB, Heimburger O, Qureshi AR, Ikizler TA, Stenvinkel P. Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int 2005, 68:2368-2374.
40. Brunelli SM, Thadhani R, Ikizler TA, Feldman HI. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int 2009, 75:961-968.